Corient Private Wealth LLC Sells 2,746 Shares of West Pharmaceutical Services, Inc. (NYSE:WST)

Corient Private Wealth LLC lessened its holdings in West Pharmaceutical Services, Inc. (NYSE:WST - Free Report) by 2.6% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 104,081 shares of the medical instruments supplier's stock after selling 2,746 shares during the period. Corient Private Wealth LLC owned 0.14% of West Pharmaceutical Services worth $34,093,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors also recently modified their holdings of the company. Fiera Capital Corp lifted its holdings in shares of West Pharmaceutical Services by 13.2% during the fourth quarter. Fiera Capital Corp now owns 140,893 shares of the medical instruments supplier's stock worth $46,151,000 after buying an additional 16,418 shares in the last quarter. Trust Point Inc. increased its stake in shares of West Pharmaceutical Services by 321.0% in the 4th quarter. Trust Point Inc. now owns 3,183 shares of the medical instruments supplier's stock valued at $1,043,000 after purchasing an additional 2,427 shares during the last quarter. Savant Capital LLC grew its holdings in shares of West Pharmaceutical Services by 15.0% during the 4th quarter. Savant Capital LLC now owns 1,003 shares of the medical instruments supplier's stock valued at $329,000 after purchasing an additional 131 shares during the last quarter. Nomura Asset Management Co. Ltd. increased its holdings in shares of West Pharmaceutical Services by 22.4% during the third quarter. Nomura Asset Management Co. Ltd. now owns 130,345 shares of the medical instruments supplier's stock worth $39,124,000 after buying an additional 23,850 shares in the last quarter. Finally, Swedbank AB increased its holdings in West Pharmaceutical Services by 44.6% in the 3rd quarter. Swedbank AB now owns 7,195 shares of the medical instruments supplier's stock worth $2,160,000 after purchasing an additional 2,220 shares in the last quarter. 93.90% of the stock is owned by institutional investors.

Remove Ads

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on WST shares. Evercore ISI began coverage on shares of West Pharmaceutical Services in a research note on Tuesday. They set an "outperform" rating and a $275.00 price target for the company. Citigroup initiated coverage on West Pharmaceutical Services in a research report on Wednesday, January 8th. They set a "buy" rating and a $400.00 price objective for the company. KeyCorp decreased their target price on shares of West Pharmaceutical Services from $470.00 to $325.00 and set an "overweight" rating for the company in a research report on Friday, February 14th. Deutsche Bank Aktiengesellschaft raised shares of West Pharmaceutical Services from a "hold" rating to a "buy" rating and set a $250.00 target price for the company in a research note on Friday, February 14th. Finally, UBS Group upgraded West Pharmaceutical Services from a "neutral" rating to a "buy" rating and increased their price target for the stock from $350.00 to $390.00 in a report on Thursday, December 12th. Two analysts have rated the stock with a hold rating and six have given a buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $332.50.

West Pharmaceutical Services Stock Up 0.7 %

Shares of WST stock traded up $1.52 on Friday, reaching $229.03. 2,640,938 shares of the company were exchanged, compared to its average volume of 634,008. The company has a debt-to-equity ratio of 0.08, a current ratio of 2.79 and a quick ratio of 2.23. The company has a 50-day moving average of $276.85 and a 200-day moving average of $301.09. The company has a market cap of $16.56 billion, a price-to-earnings ratio of 34.23, a PEG ratio of 6.74 and a beta of 1.09. West Pharmaceutical Services, Inc. has a one year low of $197.01 and a one year high of $400.88.

West Pharmaceutical Services (NYSE:WST - Get Free Report) last announced its quarterly earnings results on Thursday, February 13th. The medical instruments supplier reported $1.82 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.75 by $0.07. West Pharmaceutical Services had a return on equity of 18.60% and a net margin of 17.03%. The business had revenue of $748.80 million for the quarter, compared to analyst estimates of $739.59 million. Analysts anticipate that West Pharmaceutical Services, Inc. will post 6.62 earnings per share for the current year.

West Pharmaceutical Services Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, May 7th. Shareholders of record on Wednesday, April 30th will be issued a dividend of $0.21 per share. The ex-dividend date is Wednesday, April 30th. This represents a $0.84 annualized dividend and a yield of 0.37%. West Pharmaceutical Services's payout ratio is 12.56%.

West Pharmaceutical Services Profile

West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.